engineered
for
clinical translation
developing novel therapeutics
through proprietary RNA production, delivery, and synthesis technologies
Crafton Biotechnology selected for the 2026 Aichi Deeptech Launchpad with R&D funding
Crafton Biotechnology Co., Ltd. and FunPep Co., Ltd. Enter into Joint Research Agreement for Therapeutic mRNA Vaccines — Combining Antibody-Inducing Peptide Technology with Proprietary mRNA Technology —
Crafton Biotechnology Enters into an Agreement for the Manufacturing and Commercialization of a Novel Phosphoramidite Reagent to Enable High‑Purity mRNA Synthesis
We Are Exhibiting at JHVS 2025
Award & Media Coverage Announcement
Innovative mRNA Drug
Development Technology
mRNA vaccines and medicines have attracted significant attention in recent years. We can design and synthesize high-quality mRNA through our science and technology. We will contribute to the development of innovative medicines by collaborating with various partners.
Crafton is developing a focused pipeline of mRNA programs designed to validate and apply its high-purity mRNA platform.
Our strategy is to prioritize indications where mRNA quality, dose efficiency, tolerability, and manufacturing speed may provide meaningful clinical or development advantages.
In parallel, Crafton pursues platform collaborations to evaluate PureCap across external mRNA payloads and disease areas.
Creating the Future with our proprietary Technology
Our aim is to develop new medicines for diseases with unmet medical needs by enhancing our proprietary mRNA platform technology through collaborations with academia and pharmaceutical companies.
To achieve this objective, we will partner with various stakeholders to break down barriers between disciplines, divisions, and cultures, and fearlessly tackle challenging obstacles to expedite the delivery of innovative medicines.
